What SEC filings does Cytosorbents Corporation submit to the SEC?

Cytosorbents Corporation (CTSO) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about CTSO?

A Form 4 for CTSO discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from Cytosorbents Corporation?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for CTSO?

The 10-K is Cytosorbents Corporation's annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all CTSO SEC filings directly on EDGAR?

You can view all historical Cytosorbents Corporation filings on the SEC EDGAR company page for CTSO. Each filing card on this page links directly to the original SEC document.

How often does Cytosorbents Corporation file with the SEC?

Cytosorbents Corporation files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling CTSO shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

CTSO SEC Filing News — Cytosorbents Corporation

Latest SEC filings for Cytosorbents Corporation (CTSO) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-09-23.

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications, as well…

Sector: Healthcare Industry: Medical Devices Market Cap: $15.6M CIK: 1175151

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

Rule-based classifications for CTSO currently lean bullish. Of the 20 displayed SEC filing records, 6 carry bullish classifications versus 0 bearish classifications. These labels summarize filing attributes; they are not recommendations, probabilities, or evidence of future price direction. There were 6 insider transactions (Form 4) in this period.

CTSO Filing Activity Snapshot 2026-03-25 — 2026-09-23

Insider Transactions (Form 4)

6 buys vs 0 sells

Net insider buying in this period — more purchases than sales reported.

Largest Form 144 Filing

$104.9K

Chan Phillip P. (Director, Chief Executive Officer) · 2026-06-15

261,469 shares · Form 4

Insider Transactions 6 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 6 filings in this group are Form 4s for Cytosorbents Corporation.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 6 insider filings shown, the breakdown is 6 open-market purchase. 6 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Open-market purchase ×6: The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Form 4 Open-market purchase Insider Buying 2026-09-16

CTSO insider Chan Phillip P. (Director, Chief Executive Officer) bought 3,774 shares (~$22.6K)

Chan Phillip P., listed as Director, Chief Executive Officer at Cytosorbents Corp, reported an open-market purchase of 3,774 CTSO shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	3,774	$6.00	$22.6K

Filing: Form 4 (Insider Transaction) Insider: Chan Phillip P. (Director, Chief Executive Officer) Shares: 3,774 Est. Value: $22.6K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market purchase Insider Buying 2026-09-16

CTSO insider Capponi Vincent (President and COO) bought 2,073 shares (~$12.5K)

Capponi Vincent, listed as President and COO at Cytosorbents Corp, reported an open-market purchase of 2,073 CTSO shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	1,800	$6.07	$10.9K
`P`	Open-market purchase	273	$5.90	$1.6K

Filing: Form 4 (Insider Transaction) Insider: Capponi Vincent (President and COO) Shares: 2,073 Est. Value: $12.5K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market purchase Insider Buying 2026-09-16

CTSO insider Sobel Alan D. (Director) bought 2,500 shares (~$15.3K)

Sobel Alan D., listed as Director at Cytosorbents Corp, reported an open-market purchase of 2,500 CTSO shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	1,900	$6.12	$11.6K
`P`	Open-market purchase	500	$6.05	$3.0K
`P`	Open-market purchase	100	$6.01	$601.00

Filing: Form 4 (Insider Transaction) Insider: Sobel Alan D. (Director) Shares: 2,500 Est. Value: $15.3K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market purchase Insider Buying 2026-09-09

CTSO insider Chan Phillip P. (Director, Chief Executive Officer) bought 200,000 shares (~$70.0K)

Chan Phillip P., listed as Director, Chief Executive Officer at Cytosorbents Corp, reported an open-market purchase of 200,000 CTSO shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	200,000	$0.35	$70.0K

Filing: Form 4 (Insider Transaction) Insider: Chan Phillip P. (Director, Chief Executive Officer) Shares: 200,000 Est. Value: $70.0K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market purchase Insider Buying 2026-06-16

CTSO insider MARIANI PETER J (Chief Financial Officer) bought 100,000 shares (~$44.0K)

MARIANI PETER J, listed as Chief Financial Officer at Cytosorbents Corp, reported an open-market purchase of 100,000 CTSO shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	100,000	$0.44	$44.0K

Filing: Form 4 (Insider Transaction) Insider: MARIANI PETER J (Chief Financial Officer) Shares: 100,000 Est. Value: $44.0K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market purchase Insider Buying 2026-06-15

CTSO insider Chan Phillip P. (Director, Chief Executive Officer) bought 261,469 shares (~$104.9K)

Chan Phillip P., listed as Director, Chief Executive Officer at Cytosorbents Corp, reported an open-market purchase of 261,469 CTSO shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	251,136	$0.40	$100.5K
`P`	Open-market purchase	10,333	$0.43	$4.4K

Filing: Form 4 (Insider Transaction) Insider: Chan Phillip P. (Director, Chief Executive Officer) Shares: 261,469 Est. Value: $104.9K

View on SEC EDGAR → Open Filing Document →

Material Events 10 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 10 in this period for Cytosorbents Corporation. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-09-23

CTSO filed 8-K — material company event

Cytosorbents Corp filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.